Phase IIb study of pembrolizumab combined with S‐1 + oxaliplatin or S‐1 + cisplatin as first‐line chemotherapy for gastric cancer

The KEYNOTE‐659 study evaluated the efficacy and safety of first‐line pembrolizumab plus S‐1 and oxaliplatin (SOX) (cohort 1) or S‐1 and cisplatin (SP) (cohort 2) for advanced gastric/gastroesophageal junction (G/GEJ) cancer in Japan. Herein, we update the results of cohort 1 and describe the result...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Kensei, Minashi, Keiko, Sakai, Daisuke, Nishina, Tomohiro, Omuro, Yasushi, Tsuda, Masahiro, Iwagami, Shiroh, Kawakami, Hisato, Esaki, Taito, Sugimoto, Naotoshi, Oshima, Takashi, Kato, Ken, Amagai, Kenji, Hosaka, Hisashi, Komine, Keigo, Yasui, Hisateru, Negoro, Yuji, Ishido, Kenji, Tsushima, Takahiro, Han, Shirong, Shiratori, Shinichi, Takami, Tomoko, Shitara, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357620/
https://www.ncbi.nlm.nih.gov/pubmed/35701865
http://dx.doi.org/10.1111/cas.15462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357620/
https://www.ncbi.nlm.nih.gov/pubmed/35701865
http://dx.doi.org/10.1111/cas.15462

Ejemplares similares